ES2183811T3 - Tratamiento de enfermedades tumorigenas con un hsv modificado. - Google Patents

Tratamiento de enfermedades tumorigenas con un hsv modificado.

Info

Publication number
ES2183811T3
ES2183811T3 ES93907093T ES93907093T ES2183811T3 ES 2183811 T3 ES2183811 T3 ES 2183811T3 ES 93907093 T ES93907093 T ES 93907093T ES 93907093 T ES93907093 T ES 93907093T ES 2183811 T3 ES2183811 T3 ES 2183811T3
Authority
ES
Spain
Prior art keywords
expression
treatment
methods
cell death
programmed cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93907093T
Other languages
English (en)
Inventor
Bernard Roizman
Joany Chou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arch Development Corp
Original Assignee
Arch Development Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25335240&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2183811(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Arch Development Corp filed Critical Arch Development Corp
Application granted granted Critical
Publication of ES2183811T3 publication Critical patent/ES2183811T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)

Abstract

LA INVENCION SE REFIERE A METODOS DE TRATAMIENTO DE MUERTE PROGRAMADA DE CELULAS (APOPTOSIS) A TRAVES DEL USO DEL GEN GAMMA1 34.5 DEL HSV-1 O DE PRODUCTO DE SU EXPRESION, ICP34.5. EL GEN Y SU EXPRESION HAN DEMOSTRADO QUE SON REQUERIDOS PARA LA NEUROVIRULENCIA DEL HSV-1, Y EN PARTICULAR, PARA ACTUAR COMO INHIBIDOR DE LA MUERTE PROGRAMADA DE CELULAS NEURONALES QUE PERMITE LA REPLICACION VIRAL. EL USO DE LA TERAPIA DE GENES, O DE LA PROTEINA MISMA, PUEDE ESPERARSE QUE RESULTE EN LA INHIBICION DE LA MUERTE DE CELULAS EN DIFERENTES ENFERMEDADES NEURODEGENERATIVAS. ESTA INVENCION TAMBIEN SE REFIERE A NUEVOS VECTORES PARA LA TERAPIA DE GENES, QUE INCLUYEN EL VIRUS MODIFICADO DEL HERPES. SE PRESENTAN METODOS PARA CONDUCIR PRUEBAS PARA SUBSTANCIAS CAPACES DE MINIMIZAR, POTENCIAR O INHIBIR LA EXPRESION DEL GAMMA1 34.5 O LA ACTIVIDAD DEL ICP34.5. TAMBIEN SE HAN DESCUBIERTO METODO PARA EL TRATAMIENTO DE ENFERMEDADES TUMOROGENICAS, QUE INCLUYEN EL CANCER, Y PARA EL TRATAMIENTO DEL HERPES O DE OTRAS INFECCIONES VIRALES UTILIZANDO INHIBIDORES DE LA EXPRESION DEL GAMMA1 34.5 O DE LA ACTIVIDAD DE ICP34.5.
ES93907093T 1992-03-31 1993-02-26 Tratamiento de enfermedades tumorigenas con un hsv modificado. Expired - Lifetime ES2183811T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86123392A 1992-03-31 1992-03-31

Publications (1)

Publication Number Publication Date
ES2183811T3 true ES2183811T3 (es) 2003-04-01

Family

ID=25335240

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93907093T Expired - Lifetime ES2183811T3 (es) 1992-03-31 1993-02-26 Tratamiento de enfermedades tumorigenas con un hsv modificado.

Country Status (10)

Country Link
US (2) US6172047B1 (es)
EP (1) EP0675961B1 (es)
JP (2) JP3974167B2 (es)
AT (1) ATE228570T1 (es)
AU (1) AU682463B2 (es)
CA (1) CA2132976C (es)
DE (1) DE69332525T2 (es)
DK (1) DK0675961T3 (es)
ES (1) ES2183811T3 (es)
WO (1) WO1993019591A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770274B1 (en) 1990-09-14 2004-08-03 The General Hospital Corporation Viral mutant HSV mediated destruction of neoplastic cells
US6040169A (en) * 1991-01-31 2000-03-21 Medical Research Council Herpes simplex virus-1 deletion variants and vaccines thereof
US5763217A (en) * 1993-11-10 1998-06-09 University Of British Columbia Method of using, process of preparing and composition comprising recombinant herpesvirus vectors
US6699468B1 (en) * 1994-06-23 2004-03-02 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
GB9415320D0 (en) * 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
US5834216A (en) * 1995-09-06 1998-11-10 Arch Development Corporation Screening methods for the identification of inducers and inhibitors of programmed cell death (apoptosis)
AU6964596A (en) * 1995-09-11 1997-04-01 Arch Development Corporation Materials and methods for treating neurodegenerative diseases and for screening for candidate apoptosis inhibitors and inducers
AU1550797A (en) * 1996-01-25 1997-08-20 Medical Research Council Treatment of non-neuronal cancer using hsv mutant
GB9615794D0 (en) 1996-07-26 1996-09-04 Medical Res Council Mutant herpes simplex virus strains and uses thereof
JPH1087503A (ja) * 1996-09-06 1998-04-07 Nippon Chem Res Kk 神経系腫瘍細胞のアポトーシス剤
PT1019524E (pt) * 1997-01-31 2004-12-31 Arch Dev Corp Metodos para identificar indutores e inibidores da morte celular programada
US5795713A (en) * 1997-02-04 1998-08-18 Arch Development Corporation Methods for identifying inducers and inhibitors of programmed cell death
US6379674B1 (en) 1997-08-12 2002-04-30 Georgetown University Use of herpes vectors for tumor therapy
US20040151697A1 (en) * 1998-01-08 2004-08-05 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
WO2000007618A2 (en) * 1998-07-31 2000-02-17 Centre De Recherche Du Centre Hospitalier De L'universite De Montreal Anti-apoptotic compositions comprising the r1 subunit of herpes simplex virus ribonucleotide reductase or its n-terminal portion; and uses thereof
US6774119B1 (en) * 1999-04-26 2004-08-10 Cedars-Sinai Medical Center Herpes simplex virus type 1 (hsv-1)-derived vector for selectively inhibiting malignant cells and methods for its use to treat cancers and to express desired traits in malignant and non-malignant mammalian cells
US6897057B1 (en) * 1999-08-31 2005-05-24 The General Hospital Corporation Cell-specific and/or tumor-specific promoter retargeting of herpes γ 34.5 gene expression
ES2254359T3 (es) 2000-01-21 2006-06-16 Biovex Limited Cepa viral para el tratamiento oncolitico de canceres.
AU2003216502B2 (en) * 2002-03-01 2008-04-10 Sloan-Kettering Institute For Cancer Research Prevention of recurrence and metastasis of cancer
JP2004099584A (ja) * 2002-05-02 2004-04-02 Keio Gijuku Ｈｓｖを用いた抗腫瘍剤
EP1552016A4 (en) * 2002-09-23 2008-05-14 Macrogenics Inc VACCINE IDENTIFICATION METHODS AND VACCINATION COMPOSITIONS COMPRISING NUCLEIC ACID SEQUENCES AND / OR HERPES VIRUS FAMILY POLYPEPTIDES
US7592169B2 (en) * 2003-04-25 2009-09-22 Medimmune, Llc Methods and compositions for treatment and prevention of HSV-2 infections and conditions
US7795419B2 (en) * 2004-05-26 2010-09-14 Rosetta Genomics Ltd. Viral and viral associated miRNAs and uses thereof
WO2006002394A2 (en) * 2004-06-24 2006-01-05 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
DE102005052622A1 (de) 2005-11-02 2007-05-03 Antonio Larcher Vorrichtung zur Extraktion eines Angelhakens
US20090273586A1 (en) * 2008-04-30 2009-11-05 Sony Ericsson Mobile Communications Ab Device and method for composing and handling messages
NZ599677A (en) * 2009-12-18 2014-10-31 Bavarian Nordic As Production of ifn-lambda by conventional dendritic cells and uses thereof
US10092626B2 (en) * 2013-12-17 2018-10-09 Yale University Anti-infective properties of antifreeze protein
SG10202108724YA (en) 2016-01-08 2021-09-29 Replimune Ltd Modified oncolytic virus

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769331A (en) 1981-09-16 1988-09-06 University Patents, Inc. Recombinant methods and materials
US4859587A (en) * 1984-06-04 1989-08-22 Institut Merieux Recombinant herpes simplex viruses, vaccines and methods
CA2039921A1 (en) * 1990-04-16 1991-10-17 Xandra O. Breakefield Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
US5328688A (en) * 1990-09-10 1994-07-12 Arch Development Corporation Recombinant herpes simplex viruses vaccines and methods
US5360893A (en) 1992-07-20 1994-11-01 University Of Colorado Foundation, Inc. DNA sequences encoding proteins used to elicit and detect programmed cell death
US5593879A (en) 1993-01-15 1997-01-14 Massachusetts Institute Of Technology Cell death genes of Drosophila melanogaster and vertebrate analogs
US5585096A (en) * 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells

Also Published As

Publication number Publication date
DE69332525T2 (de) 2003-04-17
DK0675961T3 (da) 2003-03-24
US6172047B1 (en) 2001-01-09
AU682463B2 (en) 1997-10-09
AU3781893A (en) 1993-11-08
US6340673B1 (en) 2002-01-22
JP2006335763A (ja) 2006-12-14
CA2132976A1 (en) 1993-10-14
WO1993019591A1 (en) 1993-10-14
CA2132976C (en) 2003-12-30
EP0675961B1 (en) 2002-11-27
JPH07507997A (ja) 1995-09-07
DE69332525D1 (de) 2003-01-09
EP0675961A1 (en) 1995-10-11
EP0675961A4 (en) 1996-02-28
ATE228570T1 (de) 2002-12-15
JP3974167B2 (ja) 2007-09-12

Similar Documents

Publication Publication Date Title
ES2183811T3 (es) Tratamiento de enfermedades tumorigenas con un hsv modificado.
Yu et al. The interplay between human herpes simplex virus infection and the apoptosis and necroptosis cell death pathways
Chen et al. New insights into the role of nuclear factor-κB in cell growth regulation
Aubert et al. Modulation of apoptosis during herpes simplex virus infection in human cells
Aubert et al. Induction and prevention of apoptosis in human HEp-2 cells by herpes simplex virus type 1
ATE251672T1 (de) Hsv stamm mit mangel für funktionelle icp27 und icp34.5 genen
DK1252322T3 (da) Herpesvirusstamme til genterapi
Jones Bovine herpes virus 1 (BHV-1) and herpes simplex virus type 1 (HSV-1) promote survival of latently infected sensory neurons, in part by inhibiting apoptosis
BR9408025A (pt) Compostos de peptidila e seu uso terapêutico como inibidores de metaloproteinases
Norbury et al. Cdc2 activation is not required for thymocyte apoptosis
FI951298A0 (fi) 2-amino-4-fenyyli-4-oksovoihappojohdannaiset, joilla on kynureninaasia ja/tai kynureniini-3-hydroksylaasia inhiboiva aktiivisuus
EP0616032A3 (en) Preventive or therapeutic agents for Alzheimer's disease, a seven-test method, and human tau protein kinase.
DE60027870D1 (de) Genetische manipulierte herpesviren zur behandlung von tumoren
WO1998004709A3 (en) Herpes simplex virus ICP4 is an inhibitor of apoptosis
Amin et al. HSV-1 infection: role of viral proteins and cellular receptors
Yedowitz et al. Herpes simplex virus 2 modulates apoptosis and stimulates NF-κB nuclear translocation during infection in human epithelial HEp-2 cells
Schang et al. Chromatin-mediated epigenetic regulation of HSV-1 transcription as a potential target in antiviral therapy
Murata et al. Herpes simplex virus type 2 US3 blocks apoptosis induced by sorbitol treatment
ATE272713T1 (de) Ehv-1 vektoren
Liu et al. Murine coronavirus-induced oligodendrocyte apoptosis is mediated through the activation of the Fas signaling pathway
DE69721484D1 (de) Nukleosidderivative in kombinationspräparaten zur behandlung von hsv krankheiten
Hong et al. Reduced expression of calsenilin/DREAM/KChIP3 in the brains of kainic acid-induced seizure and epilepsy patients
BR9910594A (pt) Vìrus de herpes simplex, uso de um vìrus de herpessimplex, composição farmacêutica e processospara estudar a função de um gene heterólogo emuma célula de mamìfero, para produzir um vìrus deherpes simplex e para tratar um distúrbio ou uma lesãodo sistema nervoso de um mamìfero
WO1995007708A3 (en) Therapeutic use of the retinoblastoma susceptibility gene product
Rieber et al. UV radiation induces DNA fragmentation and cell death in B16 melanoma sensitized by bromodeoxyuridine: impaired c-jun induction and defective tyrosine phosphorylation signaling